Evolus Reports Third Quarter 2022 Results and Provides Busin

Reported Sales Up 27% to $33.9 Million; Success of ‘Switch Your Tox’ Promotion Contributes to $3.5 Million Incremental Increase in Deferred Revenue Over Q2 and Understates Strength of Results‘Switch Your Tox’ Drives Record Consumer Rewards Redemptions and New Purchasing AccountsReiterates Full-Year 2022 Net Revenue...

Related Keywords

United States , United Kingdom , Great Britain , America , Davidk Erickson , Allergan Medytox , David Moatazedi , Exchange Commission On , Linkedin , Twitter , Evolus Inc , Nasdaq , Million Expected To Fund Company Breakeven , Exchange Commission , Eols Evolus Inc , Daewoong Pharmaceutical Co Ltd , Switch Your Tox Promotion Contributes , Incremental Increase , Understates Strength , New Purchasing , Revenue Guidance , Top End , Expense Guidance , Lower Half , Cash Position , Fund Company , Chief Executive , Switch Your Tox , Evolus Rewards , Investor Relations , Private Securities Litigation Reform Act , Medytox Settlement Agreements , Quarterly Report , Gross Profit Margin , Adjusted Gross Profit Margin , Comprehensive Loss , Consolidated Balance Sheet Data , Consolidated Cash Flows , Months Ended September , Media Contact ,